Impact of the iWHELD digital person-centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID-19 pandemic: A randomized controlled trial.
Impact of the iWHELD digital person-centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID-19 pandemic: A randomized controlled trial.
复制标题
iWHELD 以人为本的数字护理计划对 COVID-19 大流行期间居住在疗养院的痴呆症患者的生活质量、躁动和精神药物的影响：一项随机对照试验。
DOI：
10.1002/alz.13582
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Lawrenc
中科院分区：
文献类型：
--
作者：
McDermid,Joanne;Henley,William;Corbett,Anne;Williams,Gareth;Fossey,Jane;Clare,Linda;Fox,Chris;Aarsland,Dag;Khan,Zunera;Soto,Maria;Woodward-Carlton,Barbara;Cook,EsmeMoniz;Cummings,Jeffrey;Sweetnam,Adrienne;Chan,Xavier;Lawrenc
这是一项以人为中心的数字化护理计划，针对在2019冠状病毒病大流行期间适合远程交付的养老院痴呆症患者。方法在149家英国养老院进行为期16周的双组随机对照试验，比较iWHELD与常规治疗（TAU）。主要结局是总体生活质量，次要结局是躁动和精神药物的使用。结果抗精神病药改善患者生活质量的主要指标（F = 4.3,p= 0.04）和次要指标（F = 6.45,p= 0.01），减少精神药物的使用（χ2= 4.08,p= 0.04），且无躁动加重。在感染COVID - 19的参与者、基线时躁动的参与者和服用精神药物的参与者中可以看到获益。wheld可以提高生活质量和关键的健康指标，可以在大流行的挑战性条件下提供，并且应该考虑与任何新兴的神经精神症状药物治疗一起使用。亮点：siwheld是唯一的远程、数字交付的痴呆症护理养老院培训项目，改善了痴呆症患者的生活质量，减少了抗精神病药物的使用，而不会恶化烦躁不安。在研究期间感染Covid - 19的居民也从iwheld中获益
INTRODUCTIONiWHELD is a digital person‐centered care program for people with dementia in nursing homes adapted for remote delivery during the COVID‐19 pandemic.METHODSA 16‐week two‐arm cluster‐randomized controlled trial in 149 UK nursing homes compared iWHELD with treatment as usual (TAU). Primary outcome was the overall quality of life with secondary outcomes of agitation and psychotropic use.RESULTSiWHELD conferred benefit to quality of life on the primary (F = 4.3,p= 0.04) and secondary measures of quality of life (F = 6.45,p= 0.01) and reduced psychotropic medication use (χ2= 4.08,p= 0.04) with no worsening of agitation. Benefit was seen in participants who contracted COVID‐19, those with agitation at baseline, and those taking psychotropic medications.DISCUSSIONiWHELD confers benefits to quality of life and key measures of well‐being, can be delivered during the challenging conditions of a pandemic, and should be considered for use alongside any emerging pharmacological treatment for neuropsychiatric symptoms.HighlightsiWHELD is the only remote, digital delivery nursing home training programme for dementia careiWHELD improved quality of life in people with dementia and reduced antipsychotic use without worsening of agitationResidents who contracted Covid‐19 during the study also experienced benefits from iWHELDiWHELD offers a valuable, pandemic‐safe tool for improving dementia care